Portfolio company Kailera Therapeutics priced a $625 million IPO, one of biotech's largest-ever public offerings; Bain Capital entities retained roughly 20% ownership.
Kailera is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey
Kailera is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey.